Characteristic | All patients n=37 |
Sex, n (%) | |
Male | 16 (43.2) |
Female | 21 (56.8) |
Age (years), median (range) | 58 (35 to 78) |
ECOG score, n (%) | |
0 | 23 (69.7) |
1 | 10 (30.3) |
Prior therapy lines, n (%) | 35 (94.6) |
Median number (range) | 3 (0 to 10) |
Tumor type, n (%) | |
Colorectal | 11 (29.7) |
Ovarian cancer | 7 (18.9) |
Pancreas carcinoma | 7 (18.9) |
TNBC | 3 (8.1) |
Gastric carcinoma | 3 (8.1) |
Melanoma | 1 (2.7) |
NSCLC | 1 (2.7) |
Other | 4 (10.8) |
Number of cycles of study treatment | |
Selicrelumab, median (range) | 3 (1 to 16) |
Emactuzumab, median (range) | 3 (1 to 16) |
ECOG, Eastern Cooperative Oncology Group; n, number of patients; NSCLC, non-small cell lung cancer; TNBC, triple-negative breast cancer.